吉非替尼联合化疗治疗25例Ⅳ期肺腺癌的临床疗效

Clinical Efficacy of Gefitinib Combined With Chemotherapy in 25 Patients With StageⅣ Lung Adenocarcinoma

目的解析吉非替尼与化疗联合治疗Ⅳ期肺腺癌患者的作用。方法纳入我院2016年1月—2016年11月肺腺癌晚期患者,共50例,经计算机的筛选后分为对照和治疗两组,均有25例,前者仅接受化疗治疗,后者在化疗的基础上联合吉非替尼治疗,比对临床疾病控制、生存时间和不良反应情况。结果疾病控制率[治疗组(92.00%)vs.对照组(68.00%)],P <0.05;治疗组PFS显著长于对照组[(9.95±1.02)vs.(7.47±0.84)]月,P <0.05;不良反应发生率[治疗组(4.00%)vs.对照组(24.00%)]。结论晚期肺腺癌治疗管理中,化疗结合吉非替尼应用价值高,可控制肿瘤的生长,延长患者的PFS,且临床不良反应少,推荐推广。

Objective To analyze the effect of gefitinib combined with chemotherapy on patients with stageⅣlung adenocarcinoma.Methods A total of 50 patients with advanced lung adenocarcinoma from January 2016 to November 2016 were enrolled in our hospital.They were divided into control and treatment groups after computer screening,with 25 cases each.The former only received chemotherapy and the latter combined with gefitinib treatment on the basis of chemotherapy,the clinical disease control,survival time and adverse reactions were compared.Results The disease control rate[treatment group(92.00%)vs.control group(68.00%)],P<0.05;the PFS in the treatment group was significantly longer than that in the control group[(9.95±1.02)vs.(7.47±0.84)]months,P<0.05;The incidence of adverse reactions[treatment group(4.00%)vs.control group(24.00%)].Conclusion In the treatment and management of lung adenocarcinoma,chemotherapy combined with gefitinib has high application value,can control tumor growth,prolong PFS in patients,and has few clinical adverse reactions.